Published in Gene Ther on November 10, 2011
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin Cancer Res (2015) 1.61
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther (2014) 1.40
Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget (2015) 0.99
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood (2015) 0.93
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology (2016) 0.87
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses (2015) 0.87
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses (2016) 0.85
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. Oncolytic Virother (2015) 0.84
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther (2014) 0.83
Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol (2015) 0.82
How to train your oncolytic virus: the immunological sequel. Mol Ther (2014) 0.81
Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. Mol Ther (2015) 0.79
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy (2015) 0.78
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Biomedicines (2016) 0.78
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun (2017) 0.77
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol Ther Oncolytics (2014) 0.77
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. Viruses (2015) 0.77
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther (2016) 0.77
Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines (2016) 0.77
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother (2013) 0.75
Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis. Mol Ther Oncolytics (2017) 0.75
The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. Cancer Gene Ther (2014) 0.75
Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother (2016) 0.75
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother (2017) 0.75
Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res (2017) 0.75
Targeting Melanoma with Cancer-Killing Viruses. Open Virol J (2017) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet (1999) 1.79
LKB1 somatic mutations in sporadic tumors. Am J Pathol (1999) 1.79
Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res (1996) 1.77
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res (1998) 1.75
Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet (2008) 1.59
Making graphene luminescent by oxygen plasma treatment. ACS Nano (2009) 1.55
LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord (2006) 1.47
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47
PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther (2005) 1.28
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet (1998) 1.27
Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol (2011) 1.26
The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation. J Biol Chem (2000) 1.24
Rodent host specificity of European hantaviruses: evidence of Puumala virus interspecific spillover. J Med Virol (2002) 1.23
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther (2010) 1.19
Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer (1997) 1.12
Membrane binding mechanism of an RNA virus-capping enzyme. J Biol Chem (2000) 1.11
SMAD genes in juvenile polyposis. Genes Chromosomes Cancer (1999) 1.10
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther (2005) 1.08
Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat (1997) 1.06
Incidence of hantavirus infections in Belgium. Virus Res (2001) 1.05
Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther (2004) 1.04
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol (2000) 1.01
Oncolytic adenovirus based on serotype 3. Cancer Gene Ther (2010) 0.99
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res (2001) 0.98
Random mutagenesis used to probe the structure and function of Bacillus stearothermophilus alpha-amylase. Protein Eng (1990) 0.97
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Aminoglycoside antibiotics in infectious diseases. An overview. Am J Med (1986) 0.96
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry (2006) 0.95
Evaluation of Bt-toxin uptake by the non-target herbivore, Myzus persicae (Hemiptera: Aphididae), feeding on transgenic oilseed rape. Bull Entomol Res (2007) 0.92
Gene structure of a new cardiac peptide hormone: a model for heart-specific gene expression. Endocrinology (2000) 0.92
Molecular control of transgene escape from genetically modified plants. Plant Sci (2001) 0.92
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther (2007) 0.91
Lung metastasis from TTF-1 positive sigmoid adenocarcinoma. pitfalls and management. Pathologica (2013) 0.89
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol (1998) 0.89
Antimicrobial resistance in Staphylococcus spp., Escherichia coli and Enterococcus spp. in dogs given antibiotics for chronic dermatological disorders, compared with non-treated control dogs. Acta Vet Scand (2004) 0.89
In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. Int J Cancer (2013) 0.88
Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer (2013) 0.88
[Postsurgical gastric bezoar: presentation of a case of esophageal impaction]. Rev Esp Enferm Dig (1991) 0.88
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther (2006) 0.87
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther (2003) 0.87
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther (2004) 0.86
Invasive pneumococcal infections in infants up to three years of age: results of a longitudinal surveillance in North-East Italy. Ann Ig (2010) 0.86
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther (2008) 0.86
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol (2001) 0.86
Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries? Ann Oncol (2012) 0.84
The effect of a synthetic beta-1-24-eikosatetrapeptide corticotropin (30'920-Ba Ciba) on plasma corticoids and the urinary 17-KS and 17-OHCS. Acta Med Scand (1966) 0.84
Effect of boxing on some metabolic indices of muscular contraction. Int J Sports Med (1985) 0.84
Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat (1997) 0.84
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res (2001) 0.83
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther (2007) 0.83
Tula hantavirus in Belgium. Epidemiol Infect (2002) 0.83
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther (2009) 0.82
The influence of ubiquinone (Co Q10) on the metabolic response to work. J Sports Med Phys Fitness (1989) 0.82
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther (2002) 0.82
Specifically designed physical exercise programs improve children's motor abilities. Scand J Med Sci Sports (2007) 0.81
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther (2009) 0.81
Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries. Int J Cancer (2012) 0.81
Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study. Infection (1992) 0.81
X-ray studies of recombinant anti-testosterone Fab fragments: the use of PEG 3350 in crystallization. Acta Crystallogr D Biol Crystallogr (2000) 0.81
Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat (1995) 0.81
Cancer gene therapy with oncolytic adenoviruses. J BUON (2009) 0.80
Clinical pharmacology of cisplatin after intraperitoneal administration in patients with malignant ascites. J Chemother (1989) 0.79
Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features and with prognosis. Oncology (1992) 0.79
Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol (2001) 0.79
Ultrastructural characterization of calcification onset and progression in subdermally implanted aortic valves. Histochemical and spectrometric data. Histol Histopathol (2007) 0.78
[Ulcerative colitis associated with autoimmune hemolytic anemia, arterial thrombosis and dermal necrosis]. Rev Esp Enferm Apar Dig (1983) 0.78
Kinetics of platinum in cancer patients treated with cisplatin at different doses. Drugs Exp Clin Res (1987) 0.78
n-Hexane-induced parkinsonism: pathogenetic hypotheses. Mov Disord (1995) 0.78
Two-cycle cisplatin kinetics in patients with ovarian and mammary cancer. Ther Drug Monit (1987) 0.78
Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Ther (2011) 0.78
Short-term child psychiatric inpatient treatment. Place of residence as one-year outcome measure. Eur Child Adolesc Psychiatry (1996) 0.78
A three-dimensional assay for measurement of viral-induced oncolysis. Cancer Gene Ther (2007) 0.78
Free circulating magnesium and renal magnesium handling during acute metabolic acidosis in humans. Am J Nephrol (1998) 0.77